Abstract
Rituximab, a chimeric monoclonal antibody directed against CD20 of B cells, has been reported to be effective in the treatment of B-cell lymphomas and malignant and nonmalignant plasma cell-dependent diseases. We describe a 30-year-old woman with refractory pemphigus vulgaris who experienced a partial remission after treatment with rituximab. (J Am Acad Dermatol 2002;47:785-8.)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have